Abstract
Background/Objectives: In our previous systematic review, we found no convincing evidence to support rapid maxillary expansion (RME) as a treatment for pediatric obstructive sleep apnea (OSA). Subsequent clinical guidelines and expert opinion have continued to recommend this orthodontic treatment. We aimed to update our search to determine whether new controlled prospective evidence alters this conclusion. Methods: We updated our previous systematic review, searching for controlled prospective studies on RME efficacy for pediatric OSA published up to 1st February 2026. Results: Three new randomized clinical trials (RCTs) were identified in addition to the five original studies. Critically, none of the new RCTs included a watchful waiting or supportive care control arm, leaving the sole available comparison against watchful waiting unchanged: a single RCT that found no significant difference in AHI change between RME and observation. Of the remaining new RCTs, two found marginal AHI improvement with RME and one found no significant AHI reduction. Conclusions: The observed AHI improvements in studies lacking an untreated comparator cannot be distinguished from the known potential for spontaneous improvement in growing children. Extreme caution is warranted before recommending RME as a treatment for pediatric OSA.
Keywords: palatal expansion technique (MESH), rapid maxillary expansion, obstructive, sleep apnea (MESH), natural history, children
1. Introduction
Obstructive sleep apnea (OSA) represents the most severe manifestation of sleep-related disordered breathing (SRDB) [1] and affects 1–4% of the pediatric population [2]. Polysomnography is considered the gold standard for diagnosing pediatric OSA, with the apnea–hypopnea index (AHI) being the most widely used measure for both diagnosis and evaluating treatment outcomes [3]. Adenotonsillectomy (T&A)—the current gold standard treatment [4,5]—fails to improve AHI in over 20% of the patients [6]. Furthermore, a considerable proportion of patients may spontaneously improve [7,8,9,10], sparing a surgical intervention not free of morbidity [11]. Less invasive effective treatment alternatives are needed [12].
Rapid maxillary expansion (RME), a non-invasive orthodontic intervention aimed at correcting maxillary constriction, is often reported as an alternative therapeutic approach for managing pediatric OSA. In our previous systematic review, we found no compelling evidence to substantiate the efficacy of RME compared to other treatment alternatives or even watchful waiting [12]. However, subsequent expert opinion and clinical guidelines continue to recommend RME as a suitable treatment alternative for this disease [13,14,15,16].
We therefore sought to answer the following question: in children (<18 years old) with OSA, does RME improve sleep study outcomes compared to watchful waiting or alternative treatment?
2. Materials and Methods
2.1. Protocol and Registration
The protocol for this systematic review was first registered in PROSPERO (CRD42021249261) on 18 June 2021, and it was later updated on 15 October 2025. We followed the PRISMA 2020 guidelines [17] (see Supplementary Table S1).
2.2. Eligibility Criteria
Studies were included if they were experimental, such as randomized clinical trials, or quasi-experimental, like prospective longitudinal non-randomized controlled studies. The exclusion criteria were: (1) studies with adult patients, surgically assisted techniques or concomitant treatment in the intervention group, no diagnosis of OSA, no sleep study (PSG or HSAT), no data on the primary outcome (pre- and post-treatment AHI); (2) studies with patients with craniofacial, cardiorespiratory or neurological syndromes, or healthy non-OSA control patients; (3) case reports, reviews, opinions, etc.; and (4) in vitro and in vivo studies. The PICO question was: children diagnosed with OSA by PSG or HSAT (population); orthodontic maxillary expansion by means of an intraoral device intervention); watchful waiting or alternative treatment (comparison); and change between pre- and post-treatment AHI as measured in a sleep study (PSG or HSAT) (outcome).
2.3. Information Sources and Search Strategy
A search for literature was conducted electronically using PubMed, Web of Science, Embase, and Cochrane Central databases. References from original papers and review articles were cross-checked to identify additional trials. No limitation on language was considered. Authors were contacted if data was missing or incomplete. The search was updated for articles published from 1 December 2021 until 1 February 2026 (Supplementary Table S2).
2.4. Selection Process
Two independent reviewers (M.F.-B. and I.L.-I.d.M.) systematically and independently assessed both the titles and abstracts of all identified records for inclusion and exclusion criteria. If an abstract failed to provide sufficient information to reach a decision, the full text was retrieved. If reviewers disagreed, a third party (J.M.A.U.) was brought in to resolve the issue.
2.5. Data Collection Process and Items
The extraction of qualitative and quantitative data was performed using a structured data extraction form (Excel datasheet; Microsoft Corporation, Redmond, WA, USA, version 2021) by one investigator (M.F.-B.), and it was double-checked by another (I.L.-I.d.M.) (Supplementary Table S3). The data from pre- (T0) and post-treatment (T1) sleep study parameters in intervention (RME) and control groups were extracted: AHI (main outcome); lowest oxygen saturation, mean oxygen saturation (secondary outcomes). Researchers also collected data on the percentage change in AHI before and after the treatment, the proportion of patients with residual disease following the treatment, and the time elapsed between the initial and final sleep studies. If the data on AHI change was not explicitly available, it was manually calculated as the percentage of the difference between pre- and post-treatment AHI means = (AHI T0 mean − AHI T1 mean)/AHI T0 mean × 100 or AHI medians = (AHI T0 median − AHI T1 median)/AHI T0 median × 100. Cure rate, defined as an AHI < 1, was also manually calculated if unavailable as the rate of (patients with AHI T1 < 1)/(total of patients at T1) × 100. Readers should note that group-level calculations do not capture individual variability and may introduce imprecision in effect estimates.
2.6. Risk of Bias
Two reviewers (M.F.-B. and I.L.-I.d.M.) independently assessed the risk of bias using the modified Joanna Briggs Institute (JBI) critical appraisal checklist for randomized controlled trials and case–control studies [18]. In case of disagreement, a third reviewer was consulted (J.M.A.U.).
2.7. Certainty of Evidence Assessment
The GRADE framework (Grading of Recommendations Assessment, Development, and Evaluation) [19] was used to assess the certainty of the evidence across the domains of risk of bias, inconsistency, indirectness, imprecision, and publication bias. Randomized controlled trials were originally considered to provide high-certainty evidence, while observational studies were regarded as low-certainty.
3. Results
3.1. Study Selection
The updated search yielded 735 new records, 469 unduplicated. A total of 451 articles were eliminated: 341 during the title screening and 110 during the abstract screening, leaving 18 articles for a full-text review. At the end, three new studies [20,21,22] were added to the five studies [23,24,25,26,27] identified in the original systematic review [12]. A qualitative analysis was conducted. Notably, none of the three new studies included a watchful waiting or supportive care control arm—a critical gap that leaves the fundamental question of RME efficacy over natural history unanswered. The selection process is outlined in Figure 1, and rejected articles, along with their reasons for exclusion, are provided in Supplementary Table S4.
Figure 1.
PRISMA 2020 flow diagram for updated systematic reviews.
3.2. Study Characteristics
Methodology of the studies was heterogeneous and included three parallel RCTs [20,22,24], two cross-over RCTs [21,23] and three non-randomized controlled longitudinal cohorts [25,26,27] (see Table 1).
Table 1.
General characteristics of included studies.
| Authors [Reference] |
Country | Study Design |
Sleep Study | Control Group | RME (n) |
Follow-Up (Months) |
|---|---|---|---|---|---|---|
| Guilleminault et al. [23] | France, Italy | Cross-over RCT | PSG | T&A | 31 | RME: 3 T&A: 1 |
| Hoxha et al. [24] | Turkey | Parallel RCT | HSAT | WW | 15 | RME: 5.01 (0.96) WW: 5.38 (1.36) |
| Pirelli et al. [25] | Italy | NRC | HSAT | T&A | 40 | 4 |
| Villa et al. 2014 [26] | Italy | NRC | PSG | T&A | 22 | 12 |
| Villa et al. 2016 [27] | Italy | NRC | PSG | T&A MT |
21 | >6 |
| Gokce et al. [20] | Turkey | Parallel RCT | HSAT | 3 devices | 46 | 3 |
| Magalhaes et al. [21] | Brazil | Crossover RCT | PSG | T&A RME |
32 | 1st check: 6 2nd check: 12 |
| Aksilp et al. [22] | Thailand | Parallel RCT | PSG | T&A | 12 | 6 |
RME: rapid maxillary expansion; RCT: randomized controlled trial; HSAT: home sleep apnea test; PSG: polysomnography; T&A: adenotonsillectomy. NRC: non-randomized controlled; WW: watchful waiting; MT: Medical Treatment. Grey shading indicates studies included in the original review [12].
3.3. Results of Individual Studies
3.3.1. Demography and Risk Factors
We analyzed 366 patients, 219 of whom underwent RME. The studies included patients between 6 [22] and 13 [20] years old. Two studies [22,26] reported a higher number of male patients, while another study [20] found more female patients. Two studies did not report the BMI data [23,24]. Gokce et al. presented patients in the upper range of normality for Turkish 12–13-year-olds [20]. Race, socioeconomic status, or pre-term birth was not reported. One patient dropped out before treatment in the crossover RCT conducted by Guilleminault et al. [23], and another patient was lost to follow-up in the crossover RCT conducted by Magalhaes et al. due to an excessive delay before second line therapy [21]. The pediatric OSA diagnosis was confirmed through full-night PSG [21,22,23,26,27] or home sleep apnea test (HSAT) [20,24,25]. See Table 2.
Table 2.
Anthropometric and demographic characteristics of included studies.
| Authors [Reference] | Gender (M/F) |
Age Mean (SD), Years | BMI Mean (SD), kg/m2 | |
|---|---|---|---|---|
| Guilleminault et al. [23] | 14/17 | 6.5 (0.2) * | - | |
| Hoxha et al. [24] | RME WW |
14/16 | 12.27 (1.93) 11.46 (2.06) |
- |
| Pirelli et al. [25] | 43/37 | 7.1 (0.8) * | <24 | |
| Villa et al. 2014 [26] | RME T&A |
34/13 | 6.58 (1.83) † 3.7 (0.92) † |
18.82 (3.44) † 15.75 (1.82) † |
| Villa et al. 2016 [27] | RME T&A MT |
44/32 | 6.16 (1.68) 4.54 (1.69) 4.34 (1.08) |
19.91 (2.23) 16.98 (3.29) 15.86 (1.53) |
| Gokce et al. [20] | TTB TB BB |
16/30 | 12.5 12.8 13.1 |
22.2 22.8 23.2 |
| Magalhaes et al. [21] | T&A RME |
15/17 | 8.9 (2.3) 8.1 (1.1) |
16.08 (0.62) 15.77 (0.86) |
| Aksilp et al. [22] | T&A | 15/9 | 6.33(1.71) | 16.22(2.8) |
M: Male; F: Female; SD: Standard deviation; BMI: Body mass index; -: Not reported; RME: Rapid maxillary expansion; WW: Watchful waiting; MT: Medical Treatment; TTB: tooth-tissue-borne; TB: tooth-borne; BB: Bone-borne; T&A: Adenotonsillectomy. * Mean age of full sample provided only. † Statistically significant difference between T&A and RME cohorts. Grey shading indicates studies included in the original review [12].
3.3.2. Intervention and Controls
All studies performed RME with a fixed endo-oral appliance: Gokce et al. compared tooth, tooth–tissue, and bone anchorage [20], while the rest described standard tooth anchorage [21,27]. Supplementary Table S5 provides device details and activation regimes.
Aksilp et al. reported no adverse effects or complications in either RME or adenotonsillectomy treatment arms [22]. Gokce et al. reported mild gingivitis in relation to plaque aggregation [20].
3.3.3. Outcomes
Both crossover RCTs [21,23] were divided into two temporal groups: an initial cohort evaluating primary RME versus adenotonsillectomy and a subsequent cohort comparing secondary adenotonsillectomy after RME versus secondary RME after adenotonsillectomy. The main outcome, AHI, was extracted before (T0) and after (T1) treatment. Table 3 provides AHI values before (T0) and after (T1) treatment, AHI change percentage, and cure rate. Secondary outcomes (LSAT and MSAT) are reported in Table 4.
Table 3.
Sleep study primary outcomes: AHI pre- and post-intervention, percentage cured, and AHI change percentage.
| Authors [Reference] | Treatment Arm | AHI at T0
Mean (SD) |
p | AHI at T1
Mean (SD) |
% Cured T1 AHI < 1 | % ΔAHI * |
|---|---|---|---|---|---|---|
| Guilleminault et al. [23] First line |
RME | 11.1 (0.7) | 0.00 | 5.4 (0.6) | 7% (1/15) | 51% * |
| p | 0.2 | 0.53 | 0.15 | - | - | |
| T&A | 12.5 (0.8) | 0.00 | 4.9 (0.6) | 0% (0/16) | 60% * | |
| Guilleminault et al. [23] Second line |
RME after T&A | 4.9 (0.6) | 0.00 | 0.9 (0.3) | 93% (13/14) | 81% * |
| p | 0.15 | 0.49 | 0.16 | - | - | |
| T&A after RME | 5.4 (0.6) | 0.00 | 0.9 (0.3) | 94% (15/16) | 83% * | |
| Hoxha et al. [24] | RME | 2.5 (1.12) | <0.05 | 1.79 (1.05) | - | 28% * |
| p | - | n.s. | - | - | - | |
| WW | 2.67 (1.23) | <0.05 | 1.8 (1.08) | - | 33% * | |
| Pirelli et al. [25] | RME | 12.1 (4.9) | - | 5.4 (5.4) | 37% (15/40) | 55% |
| p | - | - | - | - | - | |
| T&A | - | - | - | 15% (6/40) | - | |
| Villa et al. 2014 [26] | RME | 5.81 (6.05) | 0.005 | 2.64 (3.11) | 37% (8/22) | 36% (74.63) |
| p | 0.000 | - | 0.468 | 0.408 | 0.011 | |
| T&A | 17.25 (13.94) | 0.000 | 1.79 (1.82) | 44% (11/25) | 84% (17.79) | |
| Villa et al. 2016 [27] (RME vs. T&A) |
RME | 5.6 (1.8–17.2) | <0.005 | 1.9 (0–11.8) | 38% (8/21) | 66% * |
| p | - | - | - | - | - | |
| T&A | 16.3 (6–71.5) | <0.005 | 1.3 (0–11.9) | 31% (13/42) | 92% * | |
| Villa et al. 2016 [27] (RME vs. MT) |
RME | 5.6 (1.8–17.2) | <0.005 | 1.9 (0–11.8) | 38% (8/21) | 66% * |
| p | - | - | - | - | - | |
| MT | 4.4 (0.8–31.3) | n.s. | 2.4 (0.6–21.1) | 15% (2/13) | 45% * | |
| Gokce et al. [20] | TTB | 9.2 (6.5–12.3) † | 0.280 | 8.0 (4.9–9.0) | - | 17.39% * |
| p | 0.277 | 0.857 | - | - | ||
| TB | 5.4 (1.5–12.6) † | 0.691 | 5.5 (2.7–15.1) | - | −11.11% * | |
| p | 0.277 | 0.857 | - | - | ||
| BB | 5.8 (3.6–10.7) † | 0.796 | 5.1 (4.2–8.7) | - | 8.62% * | |
| Magalhaes et al. [21] First line |
T&A first | 8.1 (6.6) | - | 2.21 | - | 72.71% * |
| p | 0.075 | - | - | |||
| RME first | 12.5 (8.0) | - | 8.36 | - | 33.12% * | |
| Magalhaes et al. [21] Second line |
RME after T&A | 2.21 | - | 2.13 | - | 3.62% * |
| p | - | - | - | - | - | |
| T&A after RME | 8.36 | - | 4.05 | - | 51.55% * | |
| Aksilp et al. [22] | RME | 6.8 [5.6–8.1] ‡ | <0.01 | 2.3 [1.15–5.7] ‡ | 16.7% | 66.2% * |
| p | >0.05 | - | 0.07 | 0.37 | - | |
| T&A | 7 [5.25–9.9] ‡ | <0.01 | 1.4 [0.7–1.85] ‡ | 41.7% | 80% * |
AHI: apnea–hypopnea index; SD: standard deviation; % ΔAHI: percentage of change in AHI between T0 and T1 assessments; -: not reported; WW: watchful waiting; TTB: tooth tissue-borne; TB: tooth-borne; BB: bone-borne; T&A: adenotonsillectomy; RME: rapid maxillary expansion; MT: medical treatment; n.s.: not significant. * % ΔAHI not reported, calculated as the percentage of the difference in pre- and post-treatment AHI means= (AHI T0 mean − AHI T1 mean)/AHI T0 mean × 100, or medians = (AHI T0 median − AHI T1 median)/AHI T0 median × 100. † mean (95% confidence interval). ‡ median [interquartile range]. Grey shading indicates studies included in the original review [12].
Table 4.
Sleep study secondary outcomes: mean oxygen saturation (MSAT), lowest oxygen saturation (LSAT).
| Authors [Reference] |
Treatment Arm | MSAT at T0 Mean (SD) |
p | MSAT at T1 Mean (SD) | LSAT at T0 Mean (SD) |
p | LSAT at T1 Mean (SD) |
|---|---|---|---|---|---|---|---|
| Guilleminault et al. [23] First line |
RME | - | - | - | 92.5 (0.4) | 0.00 | 95.9 (0.3) |
| p | - | - | - | 0.53 | 0.15 | 0.65 | |
| T&A | - | - | - | 92.1 (0.5) | 0.00 | 95.2 (0.3) | |
| Guilleminault et al. [23] Second line |
RME after T&A | - | - | - | 95.2 (0.3) | 0.00 | 98 (0.2) |
| p | - | - | - | 0.65 | 0.68 | 0.004 | |
| T&A after RME | - | - | - | 95.9 (0.3) | 0.00 | 97.6 (0.3) | |
| Hoxha et al. [24] | RME | 96.31 (0.75) | n.s. | 96.08 (0.64) | 88.08 (4.32) | n.s. | 89.75 |
| p | - | - | - | - | n.s. | - | |
| WW | 95.87 (1.36) | n.s. | 95.8 (1.15) | 89 (4.49) | n.s. | 89.5 (3.63) | |
| Pirelli et al. [25] | RME | - | - | - | 84.6 (2.7) | - | 95.2 (3.5) |
| p | - | - | - | - | - | - | |
| T&A | - | - | - | - | - | - | |
| Villa et al. 2014 [26] | RME | 96.56 (0.47) | 0.013 | 97.42 (1.84) | - | - | - |
| p | n.s. | - | n.s. | - | - | - | |
| T&A | 96.11 (2.7) | 0.013 | 97.5 (1.14) | - | - | - | |
| Villa et al. 2016 [27] (RME vs. T&A) |
RME | 97.29 (1.49) | <0.005 | 97.62 (0.86) | - | - | - |
| p | - | - | - | - | - | - | |
| T&A | 96.47 (1.79) | <0.005 | 98.03 (0.79) | - | - | - | |
| Villa et al. 2016 [27] (RME vs. MT) |
RME | 97.29 (1.49) | <0.005 | 97.62 (0.86) | - | - | - |
| p | - | - | - | - | - | - | |
| MT | 96.96 (1.16) | n.s. | 97.37 (1.21) | - | - | - | |
| Gokce et al. [20] | TTB | - | - | - | 82 (78–87) † | 0.401 | 80 (70–85) † |
| p | - | - | - | 0.713 | - | 0.557 | |
| TB | - | - | - | 81 (78–85) † | 0.887 | 84 (70–89) † | |
| p | - | - | - | 0.713 | - | 0.557 | |
| BB | - | - | - | 81 (66–86) † | 0.407 | 82 (75–88) † | |
| Magalhaes et al. [21] First line |
T&A first | - | - | - | 90.9 (2.7) | n.s. | 92.5 |
| p | - | - | - | 0.293 | n.s. | ||
| RME first | - | - | - | 86.9 (9.6) | n.s. | 88.6 | |
| Magalhaes et al. [21] Second line |
RME after T&A | - | - | - | 92.5 | n.s. | 91.7 |
| p | - | - | - | n.s. | n.s. | ||
| T&A after RME | - | - | - | 88.6 | n.s. | 91.2 | |
| Aksilp et al. [22] | RME | 98 [97.5–98] ‡ | 0.37 | 98 [98–98] ‡ | 86 [83.5–90] ‡ | 0.12 | 89.5 [86–93] ‡ |
| p | >0.05 | - | n.s. | >0.05 | - | n.s. | |
| T&A | 97.5 [96.5–98] ‡ | 0.75 | 98 [97–98] ‡ | 87 [81–87] ‡ | <0.05 | 90.5 [89–92.5] ‡ |
MSAT: Mean oxygen saturation; LSAT: lowest oxygen saturation; SD: standard deviation; -: not reported; TTB: tooth tissue-borne; TB: tooth-borne; BB: bone-borne; T&A: adenotonsillectomy; n.s.: not significant; RME: rapid maxillary expansion; MT: medical treatment; WW: watchful waiting. † mean (95% confidence interval). ‡ median [interquartile range]. Shaded cells correspond to studies already identified in our original review [12].
3.3.4. Dentofacial Inclusion Criteria
All studies reported maxillary transversal features as an indicator for the RME treatment: maxillary constriction [22,23,24,25,26,27], unilateral [21], or bilateral [20] posterior cross-bite (see Supplementary Table S5). Gokce et al. reported baseline upper intermolar average (95% confidence interval) widths in tooth-tissue-, tissue-, and bone-borne arms of 42.6 (40.99–44.21), 44.83 (42.56–47.10), and 42.69 (40.21–45.16) mm, that were widened to 47.65 (44.52–50.77), 47.98 (45.49–50.47), and 48.1 (44.98–51.21) mm, respectively, after treatment, corresponding to the average 5.04 (1.79–8.29), 3.15 (−1.10–7.41), and 5.41 (3.46–7.35) mm increase [20]. Magalhaes et al. reported an expansion goal of 2 to 3 mm overcorrection at the level of the upper molars but did not disclose either baseline or effectively attained maxillary transverse dimensions [21]. Aksilp et al. reported a baseline average intercanine width of 33.05 ± 2.06 mm in the RME arm, which increased to 37.18 ± 2.38 mm after 6 months [22].
3.3.5. Quantitative Synthesis
A quantitative synthesis of the results was omitted because the included studies showed significant differences in methods and clinical characteristics. The variations in study designs, participant demographics, treatment comparators, and outcome measurement tools precluded a meaningful quantitative pooling of data. There were no new studies comparing the RME treatment with watchful waiting. Across all eight included studies, only one—the parallel RCT by Hoxha et al. [24]—directly compared RME with watchful waiting, and it found no statistically significant difference in AHI change between groups. This finding, combined with the absence of any watchful waiting or supportive care arm in the three new RCTs, constitutes the central finding of this review: the controlled prospective evidence does not demonstrate a meaningful advantage of RME over the natural course of the disease.
3.3.6. Risk of Bias Assessment
The risk of bias was evaluated using the validated JBI critical appraisal tool [18] for randomized and quasi-randomized clinical trials [20,21,22,23,24,25,26,27], as shown in Supplementary Table S6.
3.3.7. Certainty of Evidence Assessment
According to the GRADE assessment, the overall certainty of evidence was low to very low across all evaluated outcomes (see Supplementary Table S7) [20,21,22,23,24,25,26,27]. Downgrading was primarily due to risk of bias, small sample sizes, lack of adjustment for confounding in observational data, and imprecision of effect estimates.
4. Discussion
In our previous review of the literature, we concluded that the available controlled evidence was insufficient to associate the observed improvements in pediatric OSA patients with RME treatment [12]. The latest systematic review update shows that, despite new controlled studies being published, there is still no straightforward comparison between the effects of RME and simply letting children grow without intervention. As we thoroughly discussed in the original review, the fact that pediatric OSA has proven the ability for spontaneous improvement both in robust clinical trials [6] and prospective long-term population-based cohorts [7,8,9,10] renders control—preferably with watchful waiting or supportive care measures—paramount for claiming treatment efficacy [12]. The three new RCTs identified in this update do not resolve this uncertainty: none included a watchful waiting or supportive care arm, and their findings therefore cannot be interpreted as evidence of a genuine RME treatment effect over the natural course of the disease.
Beyond the absence of an appropriate comparator, the included studies exhibit substantial methodological heterogeneity. Sleep study modalities ranged from in-laboratory PSG to HSAT, which yield systematically different AHI values and are not directly comparable. Follow-up durations varied widely (3 to >12 months), which is particularly relevant, given the time-dependent nature of spontaneous OSA improvement in growing children. These sources of heterogeneity precluded any quantitative synthesis and must be considered when interpreting apparently discrepant results across studies.
We have found three new RCTs on this topic. Unfortunately, none of them specifically addressed the potential contribution of spontaneous improvement to the observed outcomes. The first RCT compared three different RME devices and found them equally ineffective in reducing AHI [20]. The other two compared RME to the gold standard treatment, adenotonsillectomy. Magalhaes et al. presented a crossover design, in which RME provided a marginal effect on the overall AHI improvement [21]. Aksilp et al. found that RME influence on AHI was comparable to that observed in patients that underwent adenotonsillectomy, although the latter provided a significantly higher symptomatic relief [22]. Unfortunately, none of these three RCTs allowed by design a proper assessment of the potential contribution of spontaneous improvement to the observed AHI changes. Therefore, the only study comparing RME to either a watchful waiting or supportive care approach identified with our full systematic review protocol to date was the randomized clinical trial by Hoxha et al. [24]. In this RCT, the authors did not find differences in their main outcome, the AHI change, between patients allocated to receive RME compared to those who followed their natural growth and development without an intervention. Taken together, these findings are internally consistent with our original conclusion [12]: where a proper control exists, RME shows no advantage over the comparator. Where no such control exists, the observed AHI improvements are indistinguishable from spontaneous improvement.
One study from our search update appears to address this critical need for a treatment-naïve control arm: Remy et al. compared a cohort of RME patients with an untreated age-matched cohort who “did not yet receive the orthopedic treatment” [28]. However, upon full text read and data extraction, the AHI and PSG data from both arms were only available at baseline, with longitudinal follow-up limited to the RME arm alone. Similarly, Alforaidi et al. presented a prospective study that seemed to compare RME treatment outcomes with an untreated cohort who received “occlusal interference relieves when needed” only. Although their main outcome was an indirect measure of urine inflammatory markers, they reported a reduction in AHI in the RME group of −3.53 ev.h−1 and a worsening of +1.15 ev.h−1 in the control group [29]. Such control group matched age, sex, race, body mass index, and cephalometric measurements but without explicit mention of the baseline AHI or PSG parameters. The absence of the baseline diagnostic criteria in this cohort warrants extreme caution when interpreting follow-up AHI comparisons or drawing conclusions about OSA treatment efficacy. Both studies illustrate a recurrent pattern in this literature: designs that superficially resemble controlled comparisons but lack the methodological rigor to isolate the effect of RME from baseline imbalance, spontaneous improvement, or natural growth—precisely the confounders that only a properly randomized arm can control.
According to our inclusion criteria, which required either an experimental or quasi-experimental design, retrospective cohorts were excluded. A retrospective study that featured a control arm with untreated patients gathered subjective sleep apnea symptoms with the PSQ questionnaire. Notably, the results were only available in the orthodontic treatment arm [30]. The absence of objective sleep study data and the restriction of symptom assessment to treated patients undermined the ability to draw robust conclusions regarding treatment efficacy for sleep apnea in the study cohort.
Another retrospective cohort presented a robust sample size (n = 1217) and looked at a clinically relevant population, persistent OSA after adenotonsillectomy: the authors compared the short- and long-term effects of RME and other popular treatment alternatives (mandibular advancement devices and myofunctional therapy) to the positive airway pressure (PAP) treatment [31]. Unfortunately, the follow-up AHI values were missing; instead, success was measured by “recurrence-free survival”, which refers to the time until either clinical sleep-related symptoms return or AHI increases, as shown by another polysomnogram. The percentage of patients who were objectively (control PSG) rather than subjectively (clinical absence of recurrence) diagnosed with recurrent OSA was therefore unclear. Treatment success rate (defined as a reduction in AHI > 50% from the initial AHI value) was 85% in RME vs. 71.2% in PAP. The follow-up interval was 12 months after RME, immediate after mandibular advancement, but undisclosed for PAP. Longer follow-up times may allow for greater effect of spontaneous OSA improvement [32]. Likewise, a more thorough follow-up in PAP patients may expose them to a higher possibility of being identified as recurrent as compared to orthodontic counterparts that are more likely to be discharged without further control. The use of PAP therapy for mild to moderate pediatric OSA is typically reserved for children with symptoms or comorbidities [33]. Consequently, given the retrospective, non-randomized nature of the study, there may be a selection bias toward patients with a poorer prognosis. Overall, the limitations recognized in these studies exemplify and reinforce the decision not to include retrospective studies in our inclusion criteria for the systematic review. Retrospective designs are inherently unable to disentangle treatment effects from selection bias in a condition as heterogeneous and prone to spontaneous improvement as pediatric OSA. Their exclusion from this review is therefore not merely procedural but reflects a fundamental epistemological requirement: without prospective allocation, any apparent benefit of RME remains confounded.
Maxillary transverse deficiencies, which appear as a narrow or constricted upper jaw or a posterior dental crossbite, are commonly considered to be indicators for RME treatment [34]. These criteria may be subjective and often underreported [12]. In the present review update, two studies reported objective transversal measures of the maxilla; Gokce et al. patients featured maxillary intermolar widths of 42–44 mm and a net width gain of 3 to 5 mm [20]. These data depict a mildly constricted maxilla when compared to normative interfossae molar distances for 12-year-old Caucasians of 45.9 ± 3.7 mm [35]. Aksilp et al. reported maxillary intercanine widths of 32–33 mm and a 4 mm enlargement in the RME group [22], comparable to the maxillary intercanine norm for Asian 6-year-old patients of 32.11 ± 1.95 [36]. Therefore, the previously noted lack of dentofacial criteria disclosure seems to be improving [12], while it continues to represent not particularly transversally constricted maxillae. Notably, in the aforementioned excluded retrospective study by Xia et al., not only did they omit transversal measurements, but they exclusively considered sagittal (anteroposterior) criteria to select treatment candidates. Baseline craniofacial and anthropometric features were not statistically different among all four treatment arms [31]. The lack of description of paramount transverse craniofacial features for the indication of RME treatment raises additional concerns regarding both the inclusion criteria and the reproducibility of the results of this retrospective cohort. A similar limitation in the craniofacial selection criteria—only anteroposterior measurements with no regard to transversal measures whatsoever—was identified in another excluded study [37]. It may be hypothesized that patients had their maxillae transversally expanded irrespective of their transversal features. Providing treatment solely based on an OSA diagnosis (for example, using RME without evidence of transverse discrepancy) is discouraged by recent guidelines [38]. The data from the present update reinforce the concern raised in our original review [12]: patients recruited for RME trials that disclose maxillary dimensions continue to present values within or near normal ranges, which calls into question whether maxillary constriction is the pathophysiological driver of their OSA or merely a co-occurring trait used to justify intervention.
A recently published RCT compared 6- to 8-year-old patients undergoing RME with RME plus a device used to improve tongue position [39]. RME was performed in both arms. Therefore, the difference in treatment efficacy could be only attributed to the myofunctional intervention, while the weight of RME itself in the overall AHI improvement remains as elusive as in uncontrolled case-series [12]. Notably, other RCTs have not found advantages of supervised myofunctional therapy in adult OSA patients [40].
The main limitation of this review, inherited from our original design, is the fact that we relied exclusively on objective sleep study outcomes (AHI, LSAT, and MSAT) to assess intervention efficacy. While AHI, our main outcome of choice, has limitations for establishing both diagnosis and treatment success [41], it remains the most accepted and used measure in pediatric OSA [3]. Most of the evidence ever used to support RME as a treatment for pediatric OSA has relied on the AHI as the main outcome indeed. Therefore, the same level of caution used to evaluate its validity should be exercised when supporting its indication. The controversy on the complexity of OSA diagnosis, its effects over children’s health and quality of life, and its correlation with diverse treatment success thresholds is beyond the scope of this review. There are dozens of screening questionnaires and tools that have been proposed for either surrogate OSA diagnosis or OSA-related symptom relief [12]. Given the significant heterogeneity and the scarcity of appropriate validation of such tools, we opted to stick to objective, widely accepted diagnostic and treatment success criteria. For instance, one study reported subjective outcomes: sleep-related quality of life as measured by a validated OSA-18 questionnaire, improved after treatment in patients of the RCT by Aksilp et al., but the resulting score was significantly (p < 0.01) better in the adenotonsillectomy arm (38.42 ± 10.6) than in the RME arm (62.42 ± 9.99), indeed [22]. Additionally, the reporting of objective outcomes is not free of limitations. There is no consensus as to which should be the AHI threshold to diagnose OSA or define treatment success: we have chosen to adopt a widely recognized AHI > 1 [4,14,42], but other thresholds (AHI > 2, AHI > 3, AHI > 5, or even those using obstructive AHI) have been proposed. Furthermore, AHI changes or cure rates were not always appropriately disclosed in the selected studies. When change in AHI was not directly reported, we opted to calculate it using group-level baseline and post-treatment means or medians. This approach may introduce inaccuracy, as percentage change derived from aggregated summary statistics does not reflect individual-level change and does not account for variance, potentially biasing effect estimates. Therefore, we encourage the reader to take this into consideration when analyzing AHI enhancement data or cure rates. Notwithstanding these limitations, the consistency of our findings across two independent systematic review updates—and the fact that the only RCT with a watchful waiting arm [24] found no difference—provides a coherent and reproducible signal: the available evidence does not support RME as an efficacious treatment for pediatric OSA.
By updating our previous systematic review, we have been able to identify new published studies that met our original inclusion criteria; however, comparisons with watchful waiting or supportive care regimes are still critically lacking. As included in our original search protocol, Cochrane Central Registry was consulted for registered ongoing or unpublished research and identified five new studies: two of them compared different types of devices [43,44], and the former has been already published and discussed hereby [39]. The other three studies compared RME with adenotonsillectomy: a parallel RCT [45], crossover RCT [46], and retrospective cohort comparison [47]. None of them featured a watchful waiting or supportive care arm either, thus precluding a true measure of the actual effect of RME in growing pediatric OSA patients. Therefore, the core question remains unanswered: does RME truly add value to the pediatric OSA treatment algorithm? For what patients? Until RCTs with watchful waiting arms are completed and published, any recommendation in favor of RME for pediatric OSA must be considered expert opinion unsupported by controlled evidence—regardless of how many uncontrolled or retrospective studies accumulate in the interim.
5. Conclusions
In summary, in this updated systematic review, we were unable to identify convincing evidence of meaningful improvement associated with RME treatment in controlled prospective studies. Comparisons with watchful waiting or supportive care strategies—essential for distinguishing genuine treatment effects from the known potential for spontaneous improvement in pediatric OSA—remain critically scarce. Comparative studies evaluating RME against other treatments have yielded conflicting results, largely due to suboptimal study designs and substantial methodological heterogeneity. Future guidelines and recommendations should emphasize the need for appropriate comparators in randomized research to address this lack of clinically significant evidence of efficacy. In the meantime, caution is warranted when attributing improvements in pediatric OSA to RME treatment.
Abbreviations
The following abbreviations are used in this manuscript:
| BMI | body mass index |
| HSAT | home sleep apnea test |
| JBI | Joanna Briggs Institute |
| OSA | obstructive sleep apnea |
| MSAT | mean oxygen saturation |
| LSAT | lowest oxygen saturation |
| PSG | polysomnography |
| RCT | randomized controlled trial |
| RME | rapid maxillary expansion |
| SRDB | sleep-related disordered breathing |
| T0 | pre-treatment assessment |
| T1 | post-treatment assessment |
| T&A | adenotonsillectomy |
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm15082976/s1, Supplementary Table S1: PRISMA 2020 checklist; Supplementary Table S2: Search strategy of all databases. Supplementary Table S3: Data items extracted. Supplementary Table S4: Potentially relevant excluded studies [28,29,30,31,33,39,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98]; Supplementary Table S5. Details of rapid maxillary expansion treatment; Supplementary Table S6: JBI critical appraisal checklist for randomized clinical trials; Supplementary Table S7: GRADE staging.
Author Contributions
Conceptualization, M.F.-B.; methodology, I.L.-I.d.M.; software, M.F.-B. and I.L.-I.d.M.; writing—original draft preparation, M.F.-B.; writing—review and editing, I.L.-I.d.M., J.M.A.U., M.L.d.L. and A.Á.R.d.L.; supervision, J.M.A.U. and J.J.A.F.-P. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The data sources presented in the study are publicly available in the referred databases.
Conflicts of Interest
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Funding Statement
The main author is supported by a research grant from the Department of Health of the Basque Government (grant number 2024222010). The publication fee was covered by III Convocatoria intramural para proyectos de investigación e innovación from Fundación Vital Fundazioa—IIS Bioaraba (Reference: BAFV23/005). The sponsor played no role in the design or conduct of the review.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
- 1.American Academy of Sleep Medicine . International Classification of Sleep Disorders. 3rd ed. AASM; Darien, IL, USA: 2023. text rev. [Google Scholar]
- 2.Lumeng J.C., Chervin R.D. Epidemiology of pediatric obstructive sleep apnea. Proc. Am. Thorac. Soc. 2008;5:242–252. doi: 10.1513/pats.200708-135MG. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Aurora R.N., Zak R.S., Karippot A., Lamm C.I., Morgenthaler T.I., Auerbach S.H., Bista S.R., Casey K.R., Chowdhuri S., Kristo D.A., et al. Practice parameters for the respiratory indications for polysomnography in children. Sleep. 2011;34:379–388. doi: 10.1093/sleep/34.3.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Marcus C.L., Brooks L.J., Draper K.A., Gozal D., Halbower A.C., Jones J., Schechter M.S., Ward S.D., Sheldon S.H., Shiffman R.N. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012;130:576–584. doi: 10.1542/peds.2012-1671. [DOI] [PubMed] [Google Scholar]
- 5.Luz Alonso-Álvarez M., Canet T., Cubell-Alarco M., Estivill E., Fernández-Julián E., Gozal D., Jurado-Luque M.J., Lluch-Roselló M.A., Martínez-Pérez F., Merino-Andreu M., et al. Documento de consenso del síndrome de apneas-hipopneas durante el sueño en niños (versión completa) [Consensus document on sleep apnea-hypopnea syndrome in children (full version) Arch. Bronconeumol. 2011;47:2–18. doi: 10.1016/S0300-2896(11)70026-6. [DOI] [PubMed] [Google Scholar]
- 6.Marcus C.L., Moore R.H., Rosen C.L., Giordani B., Garetz S.L., Taylor H.G., Mitchell R.B., Amin R., Katz E.S., Arens R., et al. Childhood Adenotonsillectomy Trial (CHAT). A randomized trial of adenotonsillectomy for childhood sleep apnea. N. Engl. J. Med. 2013;368:2366–2376. doi: 10.1056/NEJMoa1215881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Bixler E.O., Fernandez-Mendoza J., Liao D., Calhoun S., Rodriguez-Colon S.M., Gaines J., He F., Vgontzas A.N. Natural history of sleep disordered breathing in prepubertal children transitioning to adolescence. Eur. Respir. J. 2016;47:1402–1409. doi: 10.1183/13993003.01771-2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Goodwin J.L., Vasquez M.M., Silva G.E., Quan S.F. Incidence and remission of sleep-disordered breathing and related symptoms in 6- to 17-year old children—The Tucson Children’s Assessment of Sleep Apnea Study. J. Pediatr. 2010;157:57–61. doi: 10.1016/j.jpeds.2010.01.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Spilsbury J.C., Storfer-Isser A., Rosen C.L., Redline S. Remission and incidence of obstructive sleep apnea from middle childhood to late adolescence. Sleep. 2015;38:23–29. doi: 10.5665/sleep.4318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Chan K.C., Au C.T., Hui L.L., Skwan N., Wing Y.K., Li A.M. How OSA evolves from childhood to young adulthood: Natural history from a 10-year follow-up study. Chest. 2019;156:120–130. doi: 10.1016/j.chest.2019.03.007. [DOI] [PubMed] [Google Scholar]
- 11.Goldman J.L., Baugh R.F., Davies L., Skinner M.L., Stachler R.J., Brereton J., Eisenberg L.D., Roberson D.W., Brenner M.J. Mortality and major morbidity after tonsillectomy: Etiologic factors and strategies for prevention. Laryngoscope. 2013;123:2544–2553. doi: 10.1002/lary.23926. [DOI] [PubMed] [Google Scholar]
- 12.Fernández-Barriales M., Lafuente-Ibáñez de Mendoza I., Alonso-Fernández Pacheco J.J., Aguirre-Urizar J.M. Rapid maxillary expansion versus watchful waiting in pediatric OSA: A systematic review. Sleep Med. Rev. 2022;62:101609. doi: 10.1016/j.smrv.2022.101609. [DOI] [PubMed] [Google Scholar]
- 13.Ersu R., Chen M.L., Ehsan Z., Ishman S.L., Redline S., Narang I. Persistent obstructive sleep apnoea in children: Treatment options and management considerations. Lancet Respir. Med. 2023;11:283–296. doi: 10.1016/S2213-2600(22)00262-4. [DOI] [PubMed] [Google Scholar]
- 14.Ehsan Z., Ishman S.L., Soghier I., Almeida F.R., Boudewyns A., Camacho M., Carno M.A., Coppelson K., Ersu R.H., Ho A.T.N., et al. Management of Persistent, Post-adenotonsillectomy Obstructive Sleep Apnea in Children: An Official American Thoracic Society Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2024;209:248–261. doi: 10.1164/rccm.202310-1857ST. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Lele S.J., Kline N.L., Chapel A.C., Lenes-Voit F., Mitchell R.B. An overview of management strategies for pediatric obstructive sleep apnea following adenotonsillectomy. Expert Rev. Respir. Med. 2025;19:721–731. doi: 10.1080/17476348.2025.2500630. [DOI] [PubMed] [Google Scholar]
- 16.Leow L.C., Lee C.P., Venkateswaran S., Lim M.T.C., Teoh O.H., Chang R., Chee Y.C., Chong K.B., Chua A.P., Gooley J., et al. Singapore consensus statements on the management of obstructive sleep apnoea. Ann. Acad. Med. Singap. 2025;54:627–643. doi: 10.47102/annals-acadmedsg.2025153. [DOI] [PubMed] [Google Scholar]
- 17.Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Joanna Briggs Institute Critical Appraisal Tools. [(accessed on 1 February 2026)]. Available online: https://jbi.global/critical-appraisal-tools.
- 19.Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., Schünemann H.J., GRADE Working Group GRADE: An emerging consensus on rating quality of evidence strength of recommendations. BMJ. 2008;336:924–926. doi: 10.1136/bmj.39489.470347.AD. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Gokce G., Basoglu O.K., Veli I. Polygraphic evaluation of the effects of different rapid maxillary expansion appliances on sleep quality: A randomized clinical trial. Sleep Breath. 2023;27:651–659. doi: 10.1007/s11325-022-02677-0. [DOI] [PubMed] [Google Scholar]
- 21.Magalhães M.C., Normando D., Soares C.J., Araujo E., Novaes R.M.O., Teodoro V.V., Flores-Mir C., Kim K.B., Almeida G.A. Impact of adenotonsillectomy and palatal expansion on the apnea-hypopnea index and minimum oxygen saturation in nonobese pediatric obstructive sleep apnea with balanced maxillomandibular relationship: A cross-over randomized controlled trial. Pediatr. Pulmonol. 2024;59:3507–3517. doi: 10.1002/ppul.27239. [DOI] [PubMed] [Google Scholar]
- 22.Aksilp C., Pechpongsai P., Intakorn P., Chaweewannakorn C., Boonpratham S., Satravaha Y., Anuwongnukroh N., Peanchitlertkajorn S. A randomized controlled trial comparing treatment efficacy between rapid maxillary expansion and adenotonsillectomy in pediatric obstructive sleep apnea. Sleep Breath. 2025;29:256. doi: 10.1007/s11325-025-03427-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Guilleminault C., Monteyrol P.J., Huynh N.T., Pirelli P., Quo S., Li K. Adeno-tonsillectomy and rapid maxillary distraction in pre-pubertal children, a pilot study. Sleep Breath. 2011;15:173–177. doi: 10.1007/s11325-010-0419-3. [DOI] [PubMed] [Google Scholar]
- 24.Hoxha S., Kaya-Sezginer E., Bakar-Ates F., Koktürk O., Toygar-Memikoglu U. Effect of semi-rapid maxillary expansion in children with obstructive sleep apnea syndrome: 5-month follow-up study. Sleep Breath. 2018;22:1053–1061. doi: 10.1007/s11325-018-1636-4. [DOI] [PubMed] [Google Scholar]
- 25.Pirelli P., Saponara M., Guilleminault C. Forcierte Gaumennahterweiterung vor und nach Adenotonsillektomie bei Kindern mit obstruktiver Schlafapnoe. [(accessed on 13 February 2026)];Somnologie. 2012 16:125–132. doi: 10.1007/s11818-012-0560-2. Available online: https://art.torvergata.it/retrieve/handle/2108/71829/268477/ARTICOLO%20SOMNOLOGIE%202012.pdf. [DOI] [Google Scholar]
- 26.Villa M.P., Castaldo R., Miano S., Paolino M.C., Vitelli O., Tabarrini A., Mazzotta A.R., Cecili M., Barreto M. Adenotonsillectomy and orthodontic therapy in pediatric obstructive sleep apnea. Sleep Breath. 2014;18:533–539. doi: 10.1007/s11325-013-0915-3. [DOI] [PubMed] [Google Scholar]
- 27.Villa M.P., Sujanska A., Vitelli O., Evangelisti M., Rabasco J., Pietropaoli N., Banovcin P., Kheirandish-Gozal L., Gozal D. Use of the sleep clinical record in the follow-up of children with obstructive sleep apnea (OSA) after treatment. Sleep Breath. 2016;20:321–329. doi: 10.1007/s11325-015-1287-7. [DOI] [PubMed] [Google Scholar]
- 28.Remy F., Boyer E., Daniel C., Rousval E., Moisdon P., Burgart P., Bonnaure P., Godio-Raboutet Y., Guyot L., Meuric V., et al. Management of the pediatric OSAS: What about simultaneously expand the maxilla and advance the mandible? A retrospective non-randomized controlled cohort study. Sleep Med. 2022;90:135–141. doi: 10.1016/j.sleep.2022.01.007. [DOI] [PubMed] [Google Scholar]
- 29.Alforaidi S., Zreaqat M., Hassan R. Effects of Rapid Maxillary Expansion on Urinary Leukotriene E4 and Serum C-Reactive Protein Levels in Children With Obstructive Sleep Apnea and Maxillary Restriction: A Prospective Longitudinal Study. Pediatr. Pulmonol. 2025;60:e71235. doi: 10.1002/ppul.71235. [DOI] [PubMed] [Google Scholar]
- 30.Yoon A., Abdelwahab M., Bockow R., Vakili A., Lovell K., Chang I., Ganguly R., Liu S.Y., Kushida C., Hong C. Impact of rapid palatal expansion on the size of adenoids and tonsils in children. Sleep Med. 2022;92:96–102. doi: 10.1016/j.sleep.2022.02.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Xia T., Luo R., Wan M. Long-term recurrence-free survival of orthodontic treatments for Class II malocclusion as the important supplement protocol to adenotonsillectomy in children with obstructive sleep apnea syndrome: A case-control retrospective study. J. Clin. Pediatr. Dent. 2025;49:178–187. doi: 10.22514/jocpd.2025.037. [DOI] [Google Scholar]
- 32.Volsky P.G., Woughter M.A., Beydoun H.A., Derkay C.S., Baldassari C.M. Adenotonsillectomy vs observation for management of mild obstructive sleep apnea in children. Otolaryngol. Head Neck Surg. 2014;150:126–132. doi: 10.1177/0194599813509780. [DOI] [PubMed] [Google Scholar]
- 33.Ishman S.L., Maturo S., Schwartz S., McKenna M., Baldassari C.M., Bergeron M., Chernobilsky B., Ehsan Z., Gagnon L., Liu Y.C., et al. Expert Consensus Statement: Management of Pediatric Persistent Obstructive Sleep Apnea After Adenotonsillectomy. Otolaryngol. Head Neck Surg. 2023;168:115–130. doi: 10.1002/ohn.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Huang G.J., Richmond S., Vig K.W.L. Evidence-Based Orthodontics. 1st ed. Wiley-Blackwell; Chichester, UK: 2011. [Google Scholar]
- 35.Shujaat S., Kesztyüs A., Song D., Regnstrand T., Benchimol D., Nagy K., Jacobs R. Moving toward patient specificity for devising cone-beam computed tomography field-of-views: A normative maxillary skeletal dimensional analysis. Int. J. Paediatr. Dent. 2023;33:477–486. doi: 10.1111/ipd.13089. [DOI] [PubMed] [Google Scholar]
- 36.Ahn J.S., Park M.S., Cha H.S., Song H.C., Park Y.S. Three-dimensional interpretation of intercanine width change in children: A 9-year longitudinal study. Am. J. Orthod. Dentofac. Orthop. 2012;142:323–332. doi: 10.1016/j.ajodo.2012.04.012. [DOI] [PubMed] [Google Scholar]
- 37.Yang G., Liu A., Pan J., Zhao Y., Yu L., Sun L., Tong X., Li Y., Liu Y. Efficacy comparison between dentofacial orthopedic treatment and adenotonsillectomy on children with obstructive sleep apnea and skeletal class II malocclusion: A retrospective study. BMC Oral Health. 2025;25:1325. doi: 10.1186/s12903-025-06697-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Behrents R.G., Shelgikar A.V., Conley R.S., Flores-Mir C., Hans M., Levine M., McNamara J.A., Palomo J.M., Pliska B., Stockstill J.W., et al. Obstructive sleep apnea and orthodontics: An American Association of Orthodontists White Paper. Am. J. Orthod. Dentofac. Orthop. 2019;156:13–28.e1. doi: 10.1016/j.ajodo.2019.04.009. [DOI] [PubMed] [Google Scholar]
- 39.Restrepo C., Kahn S., Gozal D. Impact of Palatal Expansion With Up-Locker on Children With Sleep-Disordered-Breathing: A Clinical Trial. Pediatr. Pulmonol. 2026;61:e71424. doi: 10.1002/ppul.71424. [DOI] [PubMed] [Google Scholar]
- 40.Díaz de Terán T., Bolado J., Palomo P., Muñoz P., de Labra C., González M. Effectiveness of strenghtning oropharyngeal myofunctional therapy combined with cervical spine exercises in mild to moderate obstructive sleep apnoea. Sleep Breath. 2025;29:348. doi: 10.1007/s11325-025-03487-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Malhotra A., Ayappa I., Ayas N., Collop N., Kirsch D., Mcardle N., Mehra R., Pack A.I., Punjabi N., White D.P., et al. Metrics of sleep apnea severity: Beyond the apnea-hypopnea index. Sleep. 2021;44:zsab030. doi: 10.1093/sleep/zsab030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Baker-Smith C.M., Isaiah A., Melendres M.C., Mahgerefteh J., Lasso-Pirot A., Mayo S., Gooding H., Zachariah J., American Heart Association Athero. Hypertension and Obesity in the Young Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young Sleep-Disordered Breathing and Cardiovascular Disease in Children and Adolescents: A Scientific Statement From the American Heart Association. J. Am. Heart Assoc. 2021;10:e022427. doi: 10.1161/JAHA.121.022427. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Restrepo Serna C.C. Impact of Palatal Expansion and Up-Locker Activator on Sleep and Pharyngeal Dimensions in Children. CES University; Medellín, Colombia: 2024. ClinicalTrials.gov. [Google Scholar]
- 44.Teixeira R. Registro Brasileiro de Ensaios Clínico (ReBEC) WHO; Geneva, Switzerland: 2024. Comparison between the differential opening maxillary expander and the Hyrax expander for pediatric Obstructive Sleep Apnea: A randomized clinical trial. ReBEC: RBR-2pd4s4q. [Google Scholar]
- 45.Supakit P. Thai Clinical Trials Registry (TCTR) TCTR; Bangkok, Thailand: 2023. A randomized controlled trial comparing treatment efficacy between rapid palatal expansion and adenotonsillectomy in pediatric obstructive sleep apnea. TCTR: TCTR20230824001. [Google Scholar]
- 46.Guo F., Li Q., Ngan P., Guan G., Chen X., Yang X., Lv C., Hua F., Zhao T., He H. Impact of tonsillectomy on the efficacy of Alt-RAMEC/PFM treatment protocols in children with class III malocclusion and tonsillar hypertrophy: Protocol for a cluster randomised controlled trial. BMJ Open. 2024;14:e084703. doi: 10.1136/bmjopen-2024-084703. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Tinano M.M. Changes in Polysomnography and Rhinomanometry Parameters After Rapid Maxillary Expansion or Adenotonsilectomy in Children with Obstructive Sleep Apnea. Federal University of Minas Gerais; Belo Horizonte, Brazil: 2021. ClinicalTrials.gov. [Google Scholar]
- 48.Kim J.-E., Hwang K.-J., Kim S.-W., Liu S.Y.-C., Kim S.-J. Correlation between craniofacial changes and respiratory improvement after nasomaxillary skeletal expansion in pediatric obstructive sleep apnea patients. Sleep Breath. 2022;26:585–594. doi: 10.1007/s11325-021-02426-9. [DOI] [PubMed] [Google Scholar]
- 49.Remy F., Bonnaure P., Moisdon P., Burgart P., Godio-Raboutet Y., Thollon L., Guyot L. Preliminary results on the impact of simultaneous palatal expansion and mandibular advancement on the respiratory status recorded during sleep in OSAS children. J. Stomatol. Oral Maxillofac. Surg. 2021;122:235–240. doi: 10.1016/j.jormas.2020.07.008. [DOI] [PubMed] [Google Scholar]
- 50.Pirelli P., Fiaschetti V., Fanucci E., Giancotti A., Condo R., Saccomanno S., Mampieri G. Cone beam CT evaluation of skeletal and nasomaxillary complex volume changes after rapid maxillary expansion in OSA children. Sleep Med. 2021;86:81–89. doi: 10.1016/j.sleep.2021.08.011. [DOI] [PubMed] [Google Scholar]
- 51.Kushida C.A., Stevens J., Bennett M., Heit T., Klemp D., Raio D., Cozean J., Cozean C. Multicenter clinical trial for the treatment of obstructive sleep apnea with a non-permanent orthodontic intraoral device in children. Eur. J. Pediatr. 2025;184:424. doi: 10.1007/s00431-025-06254-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Li K., Iwasaki T., Quo S., Li C., Young K., Leary E., Guilleminault C. Persistent pediatric obstructive sleep apnea treated with skeletally anchored transpalatal distraction. Orthod. Fr. 2022;93:47–60. doi: 10.1684/orthodfr.2022.86. [DOI] [PubMed] [Google Scholar]
- 53.Pirelli P., Fiaschetti V., Mampieri G., Condo’ R., Ubaldi N., Pachi F., Giancotti A. Effect of rapid maxillary expansion on nasomaxillary structure and sleep disordered breathing in children with obstructive sleep apnoea. Aust. Dent. J. 2024;69:S112–S120. doi: 10.1111/adj.13049. [DOI] [PubMed] [Google Scholar]
- 54.Bariani R.C.B., Bigliazzi R., Badreddine F.R., Yamamoto L.H., Tufik S., Moreira G., Fujita R.R. A clinical trial on 3D CT scan and polysomnographyc changes after rapid maxillary expansion in children with snoring. Braz. J. Otorhinolaryngol. 2022;88:S162–S170. doi: 10.1016/j.bjorl.2022.04.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Bittencourt A.B.B.C., Melo-Neto C.L.M., Dos Santos G.A., da Silva E.V.F., Muraoka C.S.A.S., Bertoz A.P.M., Dos Santos D.M., Goiato M.C. Myofunctional Responses in Obstructive Sleep Apnea Syndrome in Children Following the Use of Two Oral Orthopedic Devices. J. Clin. Exp. Dent. 2025;17:e393–e398. doi: 10.4317/jced.62603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Meira ECruz M., Guilleminault C., Gozal D., Bruni O., Pirelli P. Rapid maxillary expansion in COMISA: Preliminary observations from a 12 years follow-up. Sleep. 2025;48:zsae306. doi: 10.1093/sleep/zsae306. [DOI] [PubMed] [Google Scholar]
- 57.Mastud C.S., Deshmukh S.V., Rahalkar J., Bharatwal M., Mane S., Mastud S.P. Evaluation of treatment outcomes of customized fixed intra-oral appliance with maxillary expansion and twin block in pediatric obstructive sleep apnea patients: A prospective study. Sleep Med. Res. 2024;15:113–123. doi: 10.17241/smr.2024.02124. [DOI] [Google Scholar]
- 58.Bavani S.Z., Ng E.T., Vich M.O.L. Rapid maxillary expansion and its impact on sleep apnea in children aged 5 to 8 years: A retrospective study. Dent. Press J. Orthod. 2025;30:e2524280. doi: 10.1590/2177-6709.30.5.e2524280.oar. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Bellerive A., Montpetit A., El-Khatib H., Carra M.C., Remise C., Desplats E., Huynh N. The effect of rapid palatal expansion on sleep bruxism in children. Sleep Breath. 2015;19:1265–1271. doi: 10.1007/s11325-015-1156-4. [DOI] [PubMed] [Google Scholar]
- 60.Fastuca R., Perinetti G., Zecca P.A., Nucera R., Caprioglio A. Airway compartments volume and oxygen saturation changes after rapid maxillary expansion: A longitudinal correlation study. Angle Orthod. 2015;85:955–961. doi: 10.2319/072014-504.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Fastuca R., Perinetti G., Zecca P.A., Nucera R., Caprioglio A. Multimodal airway evaluation in growing patients after rapid maxillary expansion. Eur. J. Paediatr. Dent. 2015;16:129–134. [PubMed] [Google Scholar]
- 62.Caprioglio A., Meneghel M., Fastuca R., Zecca P.A., Nucera R., Nosetti L. Rapid maxillary expansion in growing patients: Correspondence between 3-dimensional airway changes and polysomnography. Int. J. Pediatr. Otorhinolaryngol. 2014;78:23–27. doi: 10.1016/j.ijporl.2013.10.011. [DOI] [PubMed] [Google Scholar]
- 63.Schütz T.C., Dominguez G.C., Hallinan M.P., Cunha T.C., Tufik S. Class II correction improves nocturnal breathing in adolescents. Angle Orthod. 2011;81:222–228. doi: 10.2319/052710-233.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Buccheri A., Chinè F., Fratto G., Manzon L. Rapid Maxillary Expansion in Obstructive Sleep Apnea in Young Patients: Cardio-Respiratory Monitoring. J. Clin. Pediatr. Dent. 2017;41:312–316. doi: 10.17796/1053-4628-41.4.312. [DOI] [PubMed] [Google Scholar]
- 65.Pirelli P., Saponara M., Guilleminault C. Rapid maxillary expansion (RME) for pediatric obstructive sleep apnea: A 12-year follow-up. Sleep Med. 2015;16:933–935. doi: 10.1016/j.sleep.2015.04.012. [DOI] [PubMed] [Google Scholar]
- 66.Villa M.P., Rizzoli A., Rabasco J., Vitelli O., Pietropaoli N., Cecili M., Marino A., Malagola C. Rapid maxillary expansion outcomes in treatment of obstructive sleep apnea in children. Sleep Med. 2015;16:709–716. doi: 10.1016/j.sleep.2014.11.019. [DOI] [PubMed] [Google Scholar]
- 67.Guilleminault C., Huang Y.S., Quo S., Monteyrol P.J., Lin C.H. Teenage sleep-disordered breathing: Recurrence of syndrome. Sleep Med. 2013;14:37–44. doi: 10.1016/j.sleep.2012.08.010. Erratum in Sleep Med. 2013, 14, 927–928. [DOI] [PubMed] [Google Scholar]
- 68.Marino A., Ranieri R., Chiarotti F., Villa M.P., Malagola C. Rapid maxillary expansion in children with Obstructive Sleep Apnoea Syndrome (OSAS) Eur. J. Paediatr. Dent. 2012;13:57–63. [PubMed] [Google Scholar]
- 69.Villa M.P., Rizzoli A., Miano S., Malagola C. Efficacy of rapid maxillary expansion in children with obstructive sleep apnea syndrome: 36 months of follow-up. Sleep Breath. 2011;15:179–184. doi: 10.1007/s11325-011-0505-1. [DOI] [PubMed] [Google Scholar]
- 70.Villa M.P., Malagola C., Pagani J., Montesano M., Rizzoli A., Guilleminault C., Ronchetti R. Rapid maxillary expansion in children with obstructive sleep apnea syndrome: 12-month follow-up. Sleep Med. 2007;8:128–134. doi: 10.1016/j.sleep.2006.06.009. [DOI] [PubMed] [Google Scholar]
- 71.Pirelli P., Saponara M., Guilleminault C. Rapid maxillary expansion in children with obstructive sleep apnea syndrome. Sleep. 2004;27:761–766. doi: 10.1093/sleep/27.4.761. [DOI] [PubMed] [Google Scholar]
- 72.Pirelli P., Saponara M., De Rosa C., Fanucci E. Orthodontics and obstructive sleep apnea in children. Med. Clin. N. Am. 2010;94:517–529. doi: 10.1016/j.mcna.2010.02.004. [DOI] [PubMed] [Google Scholar]
- 73.Galeotti A., Gatto R., Caruso S., Piga S., Maldonato W., Sitzia E., Viarani V., Bompiani G., Aristei F., Marzo G., et al. Effects of Rapid Palatal Expansion on the Upper Airway Space in Children with Obstructive Sleep Apnea (OSA): A Case-Control Study. Children. 2023;10:244. doi: 10.3390/children10020244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Shetty A., Ratti S., Nakra P., Shetty S., Mohammed A., Saidath K. Evaluation of Soft Tissue and Airway Changes in Individuals Treated with Mini-Implant Assisted Rapid Palatal Expansion (MARPE) J. Long Term Eff. Med. Implant. 2022;32:7–18. doi: 10.1615/JLongTermEffMedImplants.2021038874. [DOI] [PubMed] [Google Scholar]
- 75.Zhao T., Ngan P., Hua F., Zheng J., Zhou S., Zhang M., Xiong H., He H. Impact of pediatric obstructive sleep apnea on the development of Class II hyperdivergent patients receiving orthodontic treatment: A pilot study. Angle Orthod. 2018;88:560–566. doi: 10.2319/110617-759.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Miano S., Rizzoli A., Evangelisti M., Bruni O., Ferri R., Pagani J., Villa M.P. NREM sleep instability changes following rapid maxillary expansion in children with obstructive apnea sleep syndrome. Sleep Med. 2009;10:471–478. doi: 10.1016/j.sleep.2008.04.003. [DOI] [PubMed] [Google Scholar]
- 77.Zhang X., He J.M., Zheng W.Y. Comparison of rapid maxillary expansion and pre-fabricated myofunctional appliance for the management of mouth breathers with Class II malocclusion. Eur. Rev. Med. Pharmacol. Sci. 2021;25:16–23. doi: 10.26355/eurrev_202101_24340. [DOI] [PubMed] [Google Scholar]
- 78.Kuroedova V.D., Chikor T.A., Makarova A.N., Kim A.A. Orthodontic treatment effect of on the condition of the upper airways. Wiad. Lek. 2016;69:734–736. [PubMed] [Google Scholar]
- 79.Izuka E.N., Feres M.F., Pignatari S.S. Immediate impact of rapid maxillary expansion on upper airway dimensions and on the quality of life of mouth breathers. Dent. Press. J. Orthod. 2015;20:43–49. doi: 10.1590/2176-9451.20.3.043-049.oar. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Alexander N., Boota A., Hooks K., White J.R. Rapid Maxillary Expansion and Adenotonsillectomy in 9-Year-Old Twins With Pediatric Obstructive Sleep Apnea Syndrome: An Interdisciplinary Effort. J. Am. Osteopath. Assoc. 2019;119:126–134. doi: 10.7556/jaoa.2019.019. [DOI] [PubMed] [Google Scholar]
- 81.Bonetti G.A., Piccin O., Lancellotti L., Bianchi A., Marchetti C. A case report on the efficacy of transverse expansion in severe obstructive sleep apnea syndrome. Sleep Breath. 2009;13:93–96. doi: 10.1007/s11325-008-0206-6. [DOI] [PubMed] [Google Scholar]
- 82.Rose E., Schessl J. Orthodontic procedures in the treatment of obstructive sleep apnea in children. J. Orofac. Orthop. 2006;67:58–67. doi: 10.1007/s00056-006-0534-8. [DOI] [PubMed] [Google Scholar]
- 83.Li K.K., Riley R., Powell N., Hester J. Skeletal expansion by gradual intraoral distraction osteogenesis for the treatment of obstructive sleep apnea. Oper. Tech. Otolaryngol.-Head Neck Surg. 2002;13:119–122. doi: 10.1053/otot.2002.127288. [DOI] [Google Scholar]
- 84.Gracco A., Bruno G., de Stefani A., Ragona R.M., Mazzoleni S., Stellini E. Combined Orthodontic and Surgical Treatment in a 8-Years-Old Patient Affected By Severe Obstructive Sleep Apnea: A Case-Report. J. Clin. Pediatr. Dent. 2018;42:79–84. doi: 10.17796/1053-4628-42.1.14. [DOI] [PubMed] [Google Scholar]
- 85.Galeotti A., Festa P., Pavone M., De Vincentiis G.C. Effects of simultaneous palatal expansion and mandibular advancement in a child suffering from OSA. Acta Otorhinolaryngol. Ital. 2016;36:328–332. doi: 10.14639/0392-100X-548. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Peanchitlertkajorn S., Assawakawintip T., Pibulniyom M., Srisan P., Pungchanchaikul P., Jaroenying R. Successful treatment of a child with Schwartz-Jampel syndrome using rapid maxillary expansion and CPAP. J. Clin. Sleep Med. 2021;17:601–604. doi: 10.5664/jcsm.9028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.de Moura C.P., Andrade D., Cunha L.M., Tavares M.J., Cunha M.J., Vaz P., Barros H., Pueschel S.M., Clemente M.P. Down syndrome: Otolaryngological effects of rapid maxillary expansion. J. Laryngol. Otol. 2008;122:1318–1324. doi: 10.1017/S002221510800279X. [DOI] [PubMed] [Google Scholar]
- 88.Taddei M., Alkhamis N., Tagariello T., D’Alessandro G., Mariucci E.M., Piana G. Effects of rapid maxillary expansion and mandibular advancement on upper airways in Marfan’s syndrome children: A home sleep study and cephalometric evaluation. Sleep Breath. 2015;19:1213–1220. doi: 10.1007/s11325-015-1141-y. [DOI] [PubMed] [Google Scholar]
- 89.Dao N., Cozean C., Chernyshev O., Kushida C., Greenburg J., Alexander J.S. Retrospective Analysis of Real-World Data for the Treatment of Obstructive Sleep Apnea with Slow Maxillary Expansion Using a Unique Expansion Dental Appliance (DNA) Pathophysiology. 2023;30:199–208. doi: 10.3390/pathophysiology30020017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Gökçe G. ClinicalTrials.gov [Internet] U.S. National Library of Medicine; Bethesda, MD, USA: 2026. [(accessed on 1 February 2026)]. Evaluation of the effects of different rapid maxillary expansion appliances on obstructive sleep apnea. Available online: https://clinicaltrials.gov/ct2/show/NCT04604392. [Google Scholar]
- 91.Valladares Neto J. ClinicalTrials.gov [Internet] U.S. National Library of Medicine; Bethesda, MD, USA: 2019. [(accessed on 1 February 2026)]. Maxillary expansion effects in children with upper airway obstruction. Available online: https://clinicaltrials.gov/ct2/show/NCT03004300. [Google Scholar]
- 92.Gökçe G. ClinicalTrials.gov [Internet] U.S. National Library of Medicine; Bethesda, MD, USA: 2020. [(accessed on 1 February 2026)]. Polygraphic evaluation of the effects of different rapid maxillary expansion appliances on sleep quality. Available online: https://clinicaltrials.gov/ct2/show/NCT04529213. [Google Scholar]
- 93.Pliska B. ClinicalTrials.gov [Internet] U.S. National Library of Medicine; Bethesda, MD, USA: 2022. [(accessed on 13 February 2026)]. Maxillary Expansion Treatment of Pediatric OSA. Available online: https://clinicaltrials.gov/ct2/show/NCT01837914. [Google Scholar]
- 94.Monteiro M.C. Ensaiosclinicos.gov.br [Internet] Faculdade de Odontologia da Universidade Federal de Uberlândia; Uberlândia, Brazil: 2020. [(accessed on 13 February 2026)]. Impact of tonsil and adenoid removal surgery and maxillary expansion on respiratory capacity in children with Obstructive Sleep Apnea Syndrome (OSA)—Randomized clinical study. Available online: https://ensaiosclinicos.gov.br/rg/RBR-5wq5s9. [Google Scholar]
- 95.Fernández-Barriales M. ClinicalTrials.gov [Internet] U.S. National Library of Medicine; Bethesda, MD, USA: 2021. [(accessed on 13 February 2026)]. Rapid Maxillary Expansion for Residual Pediatric (ERMES) Available online: https://clinicaltrials.gov/ct2/show/NCT02947464. [Google Scholar]
- 96.Machado Junior A.J. Ensaiosclinicos.gov.br [Internet] Faculdade de Ciência Médicas—Unicamp; Campinas, Brazil: 2020. [(accessed on 13 February 2026)]. Study in children with Obstructive Sleep Apnea, after surgery, treated with a dental appliance or speech therapy. Available online: https://ensaiosclinicos.gov.br/rg/RBR-222dr8. [Google Scholar]
- 97.Capenakas S.G. ClinicalTrials.gov [Internet] U.S. National Library of Medicine; Bethesda, MD, USA: 2026. [(accessed on 13 February 2026)]. Upper Airway’s Pressure Drop Analyses After Mandibular Advancement and Maxillary Expansion. Available online: https://clinicaltrials.gov/ct2/show/NCT04190953. [Google Scholar]
- 98.Liu Y. ClinicalTrials.gov [Internet] U.S. National Library of Medicine; Bethesda, MD, USA: 2018. [(accessed on 13 February 2026)]. Multi-disciplinary Diagnosis and Treatment Process and Evaluation System for Children with Sleep Disordered Breathing and Malocclusion. Available online: https://clinicaltrials.gov/ct2/show/NCT03451318. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data sources presented in the study are publicly available in the referred databases.

